Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm
Summary
The use of genotyping for 9p21 single nucleotide polymorphisms is considered investigational, including identification of patients who may be at increased risk of cardiovascular disease or its manifestations, or identification of patients who may be at increased risk for aneurysmal disease. The listed manifestations are myocardial infarction, ischemic stroke, peripheral arterial disease and coronary artery calcification, and the listed aneurysmal diseases are abdominal aortic aneurysms, intracranial aneurysms and polypoidal choroidal vasculopathy. No manufactured test kit for 9p21 genotyping has been reviewed by the FDA, and 9p21 genotyping tests are laboratory-developed tests offered by clinical laboratories licensed under CLIA for high-complexity testing.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.